JP2013529679A - 関節の処置のための注射用医薬組成物 - Google Patents
関節の処置のための注射用医薬組成物 Download PDFInfo
- Publication number
- JP2013529679A JP2013529679A JP2013517669A JP2013517669A JP2013529679A JP 2013529679 A JP2013529679 A JP 2013529679A JP 2013517669 A JP2013517669 A JP 2013517669A JP 2013517669 A JP2013517669 A JP 2013517669A JP 2013529679 A JP2013529679 A JP 2013529679A
- Authority
- JP
- Japan
- Prior art keywords
- xylitol
- injectable pharmaceutical
- joint
- polyol
- irritation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/216—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with other specific functional groups, e.g. aldehydes, ketones, phenols, quaternary phosphonium groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/428—Vitamins, e.g. tocopherol, riboflavin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/06—Flowable or injectable implant compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/24—Materials or treatment for tissue regeneration for joint reconstruction
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polymers & Plastics (AREA)
Abstract
Description
[実施例]
ヒアルロン酸塩 1g
キシリトール 4.5g
水を加えて100gにする
pHは約7.0に調整
単回又は連続注射により使用する。
非常に粘性であるが、非ニュートン剪断減粘性特性であるため、注射が容易である。滑沢作用も有する。
キシリトール 4.5g
水を加えて100gにする
pHは約7.0に調整
単回又は連続注射により使用する。
キシリトール 4.5g
レシチンエマルジョン 1g
水を加えて100gにする
pHは約7.0に調整
単回又は連続注射により使用する。
レシチンは滑沢性を与える。
ヒアルロン酸塩 1g
キシリトール 3g
緩衝生理食塩水 0.3g
水を加えて100gにする
pHは約7.0に調整
単回又は連続注射により使用する。
キシリトール 4.5g
酢酸メチルプレドニゾロン 4g(懸濁液中)
緩衝生理食塩水 0.3g
水を加えて100gにする
pHは約7.0に調整
単回又は連続注射により使用する。
キシリトール 3.0g
ジクロフェナクナトリウム 0.3g
緩衝生理食塩水 0.3g
水を加えて100gにする
pHは約7.0に調整
単回又は連続注射により使用する。
体重2〜3kgのウサギの後足の膝関節に、先の実施例に従って、以下の表に記載された通り調製された滅菌溶液を注射した。24時間後、ウサギを屠殺して関節を取り出し、滑膜の組織学的試験を実施した。
以下の組織学的所見それぞれを、0〜3で評価した。
a.滑膜表層過形成
b.フィブリンの存在
c.炎症性浸潤
d.壊死
0.5%SLS 0.25mlを注射したことによる重篤な刺激及び炎症の徴候が見出された(表1参照)。0.5%SLS 0.25mlを含む特定の化合物を注射した場合に、滑膜損傷の軽減が見出された。
ヒト軟骨試料を得て、ヒト関節摩擦試験を、Merkher Y. et .al., (2006) Tribology Letters 22: 29 - 36に記載された通り実施した。上側のヒト軟骨試料は、およそ4mm口径を有し、下側のヒト軟骨試料は、およそ6mm口径を有していた。試料1d及び2sの2種の滑沢剤を検査した。1dは、等張性塩を含まない非ニュートン粘性プロファイル製剤中の1%ヒアルロン酸ナトリウムに対応し、2sは、等張性生理食塩水の存在下であり、それゆえニュートン粘性プロファイル製剤である1%ヒアルロン酸ナトリウムに対応している。負荷10Nを、距離4mmにわたり温度36〜37℃、速度1mm/sで加えた。
Claims (18)
- キシリトールを有効成分として含む、関節内注射のために製剤された、関節の刺激を軽減若しくは低減するため又は更なる刺激の結果としての既存の関節の炎症の増悪を低減するための注射用医薬製剤。
- キシリトールが、D−キシリトールである、請求項1に記載の注射用医薬製剤。
- キシリトールが、L−キシリトール又はD,L−キシリトールである、請求項1に記載の注射用医薬製剤。
- キシリトールの濃度が、水中で0.5%〜10%の間である、請求項1に記載の注射用医薬製剤。
- 少なくとも1種のポリマーを含有する、請求項1に記載の注射用医薬製剤。
- 500,000ダルトンを超える分子量を有する陰イオン性ポリマーをさらに含む、非ニュートン剪断減粘性を有するよう製剤された請求項1に記載の注射用医薬製剤。
- 陰イオン性ポリマーが、0.01%未満の無機塩の存在下で中和されたヒアルロン酸である、請求項6に記載の注射用医薬製剤。
- 中和されたヒアルロン酸の濃度が、0.1%〜5%である、請求項7に記載の注射用医薬製剤。
- 陰イオン性ポリマーが、その塩の形態であり、製剤が、無機塩を0.01%未満で含有する、請求項6に記載の注射用医薬製剤。
- いかなる水中油又は水中ワックスエマルジョンも実質的に含まない、請求項1に記載の注射用医薬製剤。
- キシリトールが、等張濃度である、請求項1に記載の注射用医薬製剤。
- 少なくとも1種の薬学的に許容される賦形剤又は添加剤をさらに含む、請求項1に記載の注射用医薬製剤。
- 抗炎症剤、抗酸化剤、ビタミン、別のポリオール及びそれらの組み合わせからなる群から選択される少なくとも1種の更なる医薬剤を含む、請求項1に記載の注射用医薬製剤。
- 本質的にポリオール有効成分からなり、前記ポリオール有効成分がキシリトールである、請求項1に記載の注射用医薬製剤。
- 罹患関節組織に医薬組成物を注射することを含む関節の疾患、障害又は状態を処置する方法であって、前記医薬組成物がキシリトール及び陰イオン性ポリマーを含み、非ニュートン剪断減粘性を示す、方法。
- 罹患関節組織に医薬組成物を注射することを含む関節の疾患、障害疾患(disorder disease)、障害又は状態を処置する方法であって、前記医薬組成物がキシリトールと、場合により少なくとも1種の第2の治療薬とを含み、前記第2の治療薬が陰イオン性ポリマー、抗炎症剤、抗酸化剤、ビタミン、第2のポリオール又はそれらの組み合わせを含む、方法。
- 関節内注射のために製剤される注射用医薬製剤の製造におけるキシリトール及び陰イオン性ポリマーの使用であって、組成物が関節の刺激を軽減若しくは低減するため又は既存の関節の炎症の増悪を低減するために非ニュートン剪断減粘性を示す、使用。
- 関節内注射のために製剤される注射用医薬製剤の製造におけるキシリトールと場合により少なくとも1種の第2の治療薬との使用であって、前記第2の治療薬が陰イオン性ポリマー、抗炎症剤、抗酸化剤、ビタミン、第2のポリオール又はそれらの組み合わせを含み、組成物が関節の刺激を軽減若しくは低減するため又は既存の関節の炎症の増悪を低減するために非ニュートン剪断減粘性を示す、使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL206739A IL206739A (en) | 2010-06-30 | 2010-06-30 | An injectable drug containing silitol as an active substance |
IL206739 | 2010-06-30 | ||
PCT/IL2011/000495 WO2012001679A1 (en) | 2010-06-30 | 2011-06-15 | Injectable pharmaceutical compositions for the treatment of joints |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016063344A Division JP6166811B2 (ja) | 2010-06-30 | 2016-03-28 | 関節の処置のための注射用医薬組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013529679A true JP2013529679A (ja) | 2013-07-22 |
JP2013529679A5 JP2013529679A5 (ja) | 2014-07-17 |
Family
ID=43569968
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013517669A Pending JP2013529679A (ja) | 2010-06-30 | 2011-06-15 | 関節の処置のための注射用医薬組成物 |
JP2016063344A Expired - Fee Related JP6166811B2 (ja) | 2010-06-30 | 2016-03-28 | 関節の処置のための注射用医薬組成物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016063344A Expired - Fee Related JP6166811B2 (ja) | 2010-06-30 | 2016-03-28 | 関節の処置のための注射用医薬組成物 |
Country Status (9)
Country | Link |
---|---|
US (2) | US9913808B2 (ja) |
EP (1) | EP2588080B1 (ja) |
JP (2) | JP2013529679A (ja) |
KR (1) | KR101842295B1 (ja) |
CA (1) | CA2803257C (ja) |
ES (1) | ES2679279T3 (ja) |
HU (1) | HUE039724T2 (ja) |
IL (1) | IL206739A (ja) |
WO (1) | WO2012001679A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL206739A (en) | 2010-06-30 | 2016-06-30 | David Segal | An injectable drug containing silitol as an active substance |
EP4353311A3 (en) | 2015-07-20 | 2024-07-17 | The Brigham and Women's Hospital, Inc. | Shear-thinning compositions as an intravascular embolic agent |
CN111065423B (zh) * | 2017-08-22 | 2022-04-12 | 莫比斯医疗有限公司 | 用于关节润滑的脂质体制剂 |
KR20200000823A (ko) * | 2018-06-25 | 2020-01-03 | 주식회사 씨아이에스티이엠 | 인간 유도 만능 줄기세포로부터 연골세포의 펠렛을 제조하는 방법 및 이의 용도 |
JPWO2022168968A1 (ja) * | 2021-02-05 | 2022-08-11 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03236330A (ja) * | 1989-12-21 | 1991-10-22 | Nissho Corp | 炎症治療剤 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4767785A (en) * | 1984-01-18 | 1988-08-30 | Michael Georgieff | Hypocaloric preparation and intravenous method for hypocaloric treatment of patients |
IT1198449B (it) | 1986-10-13 | 1988-12-21 | F I D I Farmaceutici Italiani | Esteri di alcoli polivalenti di acido ialuronico |
US5510418A (en) * | 1988-11-21 | 1996-04-23 | Collagen Corporation | Glycosaminoglycan-synthetic polymer conjugates |
US5095037B1 (en) | 1989-12-21 | 1995-12-19 | Nissho Kk | Combined anti-inflammatory agent |
AUPM922394A0 (en) * | 1994-11-03 | 1994-11-24 | Astra Pharmaceuticals Pty Ltd | Plastic syringe with overcap |
PT790056E (pt) | 1995-08-07 | 2005-02-28 | Suntory Ltd | Preventivo ou remedio para doencas provocadas por anormalidades nos tecidos cartilaginosos |
US6294170B1 (en) * | 1997-08-08 | 2001-09-25 | Amgen Inc. | Composition and method for treating inflammatory diseases |
ATE257399T1 (de) * | 1999-10-14 | 2004-01-15 | Becton Dickinson Co | Nasales verabreichungsgerät mit zerstäuberdüse |
US6716819B2 (en) * | 2000-05-19 | 2004-04-06 | University Of Iowa Research Foundation | Use of xylitol to reduce ionic strength and activate endogenous antimicrobials for prevention and treatment of infections |
FR2833173B1 (fr) | 2001-12-10 | 2004-08-27 | Roquette Freres | Preparation antipyretique renfermant du xylitol |
JP4836797B2 (ja) * | 2003-10-23 | 2011-12-14 | 大塚製薬株式会社 | 放出制御性無菌注射アリピプラゾール製剤および方法 |
TW200716140A (en) * | 2005-06-17 | 2007-05-01 | Dynamis Therapeutics Inc | Treatment of inflammatory conditions |
US20070293587A1 (en) * | 2006-05-23 | 2007-12-20 | Haley Jeffrey T | Combating sinus, throat, and blood infections with xylitol delivered in the mouth |
CN101209344B (zh) * | 2006-12-28 | 2012-07-04 | 赵超英 | 高渗液组合物在制备促进伤口愈合的药物中的应用 |
CN101450037A (zh) * | 2007-11-28 | 2009-06-10 | 天津太平洋制药有限公司 | 一种木糖醇静脉注射液及其制备方法 |
FR2938187B1 (fr) | 2008-11-07 | 2012-08-17 | Anteis Sa | Composition injectable a base d'acide hyaluronique ou l'un de ses sels, de polyols et de lidocaine, sterilisee a la chaleur |
CN101664384B (zh) * | 2009-09-18 | 2011-09-14 | 杭州市第六人民医院 | N-乙酰半胱氨酸盐木糖醇注射液及其制备方法和应用 |
CN101669962A (zh) * | 2009-09-18 | 2010-03-17 | 杭州市第六人民医院 | 复合甘草酸氨基酸注射液及其制备方法和应用 |
IL206739A (en) | 2010-06-30 | 2016-06-30 | David Segal | An injectable drug containing silitol as an active substance |
US20140038917A1 (en) | 2011-04-19 | 2014-02-06 | Anteis S.A. | Sterile and injectable aqueous formulation for administration in the intra-articular space of an intra-articular joint |
-
2010
- 2010-06-30 IL IL206739A patent/IL206739A/en active IP Right Grant
-
2011
- 2011-06-15 JP JP2013517669A patent/JP2013529679A/ja active Pending
- 2011-06-15 US US13/807,545 patent/US9913808B2/en active Active
- 2011-06-15 ES ES11800296.3T patent/ES2679279T3/es active Active
- 2011-06-15 EP EP11800296.3A patent/EP2588080B1/en active Active
- 2011-06-15 CA CA2803257A patent/CA2803257C/en active Active
- 2011-06-15 HU HUE11800296A patent/HUE039724T2/hu unknown
- 2011-06-15 KR KR1020127033934A patent/KR101842295B1/ko active IP Right Grant
- 2011-06-15 WO PCT/IL2011/000495 patent/WO2012001679A1/en active Application Filing
-
2016
- 2016-03-28 JP JP2016063344A patent/JP6166811B2/ja not_active Expired - Fee Related
-
2017
- 2017-01-06 US US15/400,370 patent/US9707190B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03236330A (ja) * | 1989-12-21 | 1991-10-22 | Nissho Corp | 炎症治療剤 |
Non-Patent Citations (3)
Title |
---|
JPN6015017971; J. Nutr. Vol.128, 1998, pp.1811-1814 * |
JPN6015017973; Metabolism Vol.57, 2008, pp.1052-1055 * |
JPN6015017976; Clin. Diagn. Lab. Immunol. Vol.12 No.11, 2005, pp.1285-1291 * |
Also Published As
Publication number | Publication date |
---|---|
US9707190B2 (en) | 2017-07-18 |
JP6166811B2 (ja) | 2017-07-19 |
WO2012001679A1 (en) | 2012-01-05 |
CA2803257A1 (en) | 2012-01-05 |
IL206739A0 (en) | 2010-12-30 |
EP2588080A1 (en) | 2013-05-08 |
IL206739A (en) | 2016-06-30 |
EP2588080A4 (en) | 2015-01-07 |
EP2588080B1 (en) | 2018-05-16 |
US20170112782A1 (en) | 2017-04-27 |
CA2803257C (en) | 2019-01-08 |
JP2016153416A (ja) | 2016-08-25 |
US9913808B2 (en) | 2018-03-13 |
HUE039724T2 (hu) | 2019-02-28 |
ES2679279T3 (es) | 2018-08-23 |
US20130289131A1 (en) | 2013-10-31 |
KR101842295B1 (ko) | 2018-03-27 |
KR20130135731A (ko) | 2013-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6166811B2 (ja) | 関節の処置のための注射用医薬組成物 | |
Edwards | Intra-articular drug delivery: the challenge to extend drug residence time within the joint | |
US10709731B2 (en) | Materials for treating and preventing mucosa related disease | |
Gerwin et al. | Intraarticular drug delivery in osteoarthritis | |
Kang et al. | Drug delivery systems for intra-articular treatment of osteoarthritis | |
Jensen et al. | Enhanced recovery after giant ventral hernia repair | |
KR101914940B1 (ko) | 안과 질환을 치료하기 위한 안드로겐 조성물 | |
KR20130100017A (ko) | 귀 질환 치료를 위한 제어 방출형 코르티코스테로이드 조성물 및 방법 | |
US9556333B2 (en) | Biodegradable polymer formulations | |
JP2014205713A (ja) | 生体分解性徐放性ドラッグデリバリーシステム | |
JP2003501151A (ja) | 動脈再狭窄治療用装置および化合物 | |
JP6837835B2 (ja) | トレハロースの非経口投与によるタンパク質凝集ミオパシーおよび神経変性疾患の治療 | |
Batool et al. | In-situ forming implants loaded with chlorhexidine and ibuprofen for periodontal treatment: Proof of concept study in vivo | |
PT2252290T (pt) | Composição farmacêutica para utilização no tratamento e/ou prevenção de doenças osteoarticulares | |
Pontes-Quero et al. | Active viscosupplements for osteoarthritis treatment | |
JP2017529388A5 (ja) | ||
CA2903037C (en) | Pharmaceutical formulation containing glycosaminoglycan | |
BR112020024842A2 (pt) | dosagem e efeito de antagonista de c5a com vasculite associada a anca | |
JP2013508305A (ja) | 関節内又は関節周囲の投与のための注射可能な製剤 | |
US20230049822A1 (en) | Compositions comprising niclosamide for use in treating conditions associated with an abnormal inflammatory response | |
Samborski et al. | Intra‐articular treatment of arthritides and activated osteoarthritis with the 5‐HT3 receptor antagonist tropisetron. A double‐blind study compared with methylprednisolone | |
ES2973583T3 (es) | Regímenes de administración asociados a las formulaciones inyectables de paliperidona de liberación prolongada | |
Puisys | Postoperative Healing Assessment Using Cannabinoids in Oral Surgery | |
US20170079989A1 (en) | Method for treatment of osteoarthritis and other joint related injuries and conditions | |
Warren et al. | Treatment of an Unusual Infection Following Anterior Cruciate Ligament Reconstruction |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140527 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140527 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150511 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150729 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20151210 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160328 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20160406 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20160520 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170428 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170531 |